Genmab | GEN - Selling And Administration Expenses


Genmab reported DKK208M in Selling and Administration Expenses for its fiscal quarter ending in December of 2025.





Selling And Administration Expenses Change Date
Agios Pharmaceuticals USD 38.46M 4.51M Mar/2026
Amarin USD 18.97M 1.03M Dec/2025
Amgen USD 1.58B 354M Mar/2026
argenx SE USD 355M 74.62M Mar/2026
AstraZeneca USD 5.06B 455M Mar/2026
Bayer EUR 3.7B 356M Mar/2026
BioMarin Pharmaceutical USD 258.28M 63.92M Mar/2026
Demant DKK 6.09B 135M Dec/2025
Exelixis USD 139.6M 16.58M Mar/2026
Fresenius Medical Care EUR 749M 36M Mar/2026
Genmab DKK 208M 60M Dec/2025
GlaxoSmithKline GBP 2.12B 558M Mar/2026
GN Store Nord DKK 763M 688M Mar/2026
GRIFOLS EUR 281M 5.7M Mar/2026
Hikma Pharmaceutical USD 288M 149M Dec/2025
Insmed USD 247.26M 34.78M Mar/2026
Lakefront Biotherapeutics EUR 35.5M 8.91M Mar/2026
Merck EUR 1.52B 80M Mar/2026
Novartis USD 3.14B 296M Mar/2026
Regeneron Pharmaceuticals USD 647.7M 127.3M Mar/2026
Roche Holding CHF 7.28B 3.99B Dec/2025
Sanofi EUR 2.33B 419M Mar/2026
UCB EUR 1.47B 193M Dec/2025